Uploaded June 2026 | Updated September 2026, 2 weeks ago
Looking for a way to practice mindfulness while getting your steps in? Try a color walk. Choose a color before you head out the door and then focus on that color the whole time. It can help you relax and focus your mind and lower stress.
Looking for a way to practice mindfulness while getting your steps in? Try a color walk. Choose a color before you head out the door and then focus on that color the whole time. It can help you relax and focus your mind and lower stress.
![Lp(a) in Womens Health: The Missing Piece in Residual Cardiovascular Risk
Join two leading experts for an in-depth discussion on lipoprotein(a) [Lp(a)] and its emerging role in cardiovascular risk—particularly in women. Despite the 2026 ACC/AHA Dyslipidemia Guideline recommending that every adult have Lp(a) measured at least once in a lifetime, Lp(a) remains underutilized in routine clinical practice, leaving critical gaps in risk assessment and prevention.
This webinar will provide a clear, practical overview of Lp(a)—including what it is, why it is uniquely different from traditional lipid markers, and why it matters for identifying hidden cardiovascular risk. The webinar will highlight key scientific insights and review gender-specific data, examining how Lp(a) impacts cardiovascular outcomes in women across the lifespan.
Through real-world, case-based learning, participants will gain actionable strategies for incorporating Lp(a) into risk stratification and decision-making, especially within community health center settings where early detection and equitable care are essential.
Learning Objectives:
Describe the structure and biology of lipoprotein(a) and how it differs from other lipid biomarkers
Explain the clinical significance of elevated Lp(a) in cardiovascular risk assessment
Interpret emerging data on the role of Lp(a) in women’s cardiovascular health
Apply case-based approaches to integrate Lp(a) testing into everyday clinical practice
Utilize Lp(a) as a tool for improved risk stratification in community health settings
Chapters
0:00 Welcome and Background
0:51 Dr. Stephanie Saucier Talk Introduction
2:43 Lp(a) Discovery Project Intro
3:51 Speaker Introduction
4:29 Disclosures
4:44 Learning Objectives/Outline
5:07 Why Lp(a) Matters
5:57 Lp(a) Basics
7:49 How does Lp(a) Cause Disease
7:17 Lipoprotein(a) Levels and Associated ASCVD Risk
10:15 Genetic Determinants of Lp(a) Concentration
10:49 Lp(a) Lowering Therapies
12:07 Lp(a) in Women
13:01 Women’s Health and Lp(a): Key Considerations
13:53 Lp(a) testing and next steps
14:57 Translating Lp(a) Results Into Action
16:41 Historical Treatments Evaluated
17:13 Drug Therapy in ASCVD Patients
18:45 Antisense and siRNA Therapies for Lp(a) Reduction
20:13 Lipid Apheresis for Lp(a)
21:03 Apolipoprotein(a) Characterization
21:59 Antithrombotic Treatment
23:10 Taking Action on Elevated Lp(a)
23:59 Speaker Introduction
24:27 (Dr. Hilary Wagner) Case Based Learning Overview
24:37 Disclosures
24:41 Clinical Example Case #1
26:54 Clinical Example Case #2
28:51 Clinical Example Case #3
30:30 Take Home Points
31:34 Q&A
48:40 Closing Lp(a) in Womens Health: The Missing Piece in Residual Cardiovascular Risk](https://i.ytimg.com/vi/dQIFETVq9JQ/mqdefault.jpg)









